Tarlatamab for Small-Cell Lung Cancer Treatment
- What: The FDA approved Arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- When: Approved May 3, 2023, with data published October 2, 2025, in the New England Journal of Medicine.
- Why it matters: RSV causes important illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
RSV vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Tho, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Prior to the development of vaccines, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years of age or older in the United States.
The virus spreads through close contact with infected individuals, much like the common cold or flu. Symptoms can include a runny nose, cough, fever, and shortness of breath. Because these symptoms overlap with other respiratory illnesses, RSV is often misdiagnosed.
The Arexvy Vaccine: How It Works and Trial results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is crucial for the virus to enter cells, and the vaccine trains the immune system to recognize and neutralize it. The vaccine works by stimulating an immune response without introducing the live virus, making it safe for vulnerable populations.
The pivotal Phase 3 trial, published in the New England Journal of Medicine on October 2, 2025, involved over 12,600 adults aged 60 years and older. The results demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) with at least one symptom. Efficacy against severe LRTD, defined as requiring hospitalization, was 94.1%.
The trial also assessed the safety of Arexvy. The most common adverse events were local reactions at the injection site, such as pain, redness, and swelling. Serious adverse events were rare and not definitively linked to the vaccine.
| Outcome | vaccine Group (Efficacy %) | Placebo Group (%) |
|---|---|---|
| RSV-associated LRTD (≥1 symptom) | 82.6 | 5.4 |
| Severe RSV-associated LRTD (Hospitalization) | 94.1 | 1.3 |
Who Should Get the RSV Vaccine?
The Centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older may receive a dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider.This means a discussion about individual risk factors and preferences is crucial.
Individuals at higher risk of severe RSV illness should strongly consider vaccination. This includes those with:
- Chronic heart or lung disease
- Diabetes
- Weakened immune systems
- Other underlying medical conditions
It’s vital to note that the RSV vaccine is not currently recommended for everyone over 60.The decision to vaccinate should be made in consultation with a healthcare professional.